Waldenström macroglobulinemia (WM) 
Waldenström macroglobulinemia (WM) is a clinicopathologic syndrome traditionally characterized by a proliferation of lymphocytes showing varying degrees of differentiation into plasmacytoid lymphocytes and plasma cells associated with the presence of a monoclonal gammopathy in the serum. While occasionally of the IgA or IgG type, the paraproteinemia of WM is most often IgM and usually is found in serum concentrations of at least 1,000 mg/dL (10 g/L). [1] [2] [3] [4] [5] In contrast with the often clinically insignificant monoclonal gammopathies that can be found in a variety of lymphoproliferative disorders, the paraproteinemia of WM is a major factor in the pathophysiology of the disease, producing many of the associated clinicopathologic manifestations and complications including the hyperviscosity syndrome (HVS). This serious and potentially fatal clinical complication of WM is the result of increased blood viscosity caused by elevated levels of monoclonal immunoglobulin in the serum. Patients with HVS often manifest the triad of visual changes, mental status changes, and bleeding; however, they may also manifest with headache, focal neurologic impairment, hypervolemia, and congestive heart failure. Progression to coma and death may occur unless aggressive and emergency therapeutic intervention such as plasmapheresis is provided. 1, 3, 4 It is well established that the syndrome of WM is caused by lymphoplasmacytoid lymphoma (LPL) and certain other small B-cell lymphoproliferative disorders such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 1, 6 The similar association of WM with extranodal marginal zone B-cell-mucosa-associated lymphoid tissue lymphomas (EMZL/MALT-type), however, has been the subject of only rare reports [7] [8] [9] [10] ; consequently, this connection has not been stressed in the literature or clinically. In this article, we report our experience with 6 patients with well-characterized low-grade EMZL/MALTtype and concurrent laboratory findings and clinical complications typical of WM to emphasize the occasional association of EMZL/MALT-type with the clinicopathologic syndrome of WM, and the role for serum (and possibly urine) protein studies in the clinical evaluation and management of patients with EMZL/MALT-type.
Materials and Methods

Case Selection
Following the observation of 2 cases of EMZL/MALTtype associated with large monoclonal IgM paraproteinemias, we retrospectively examined records at the University of Michigan Health System, Ann Arbor, to determine whether any other such cases existed in the hospital files. Initially, the clinical immunology laboratory records were searched for patients with a monoclonal IgM paraproteinemia more than 1,000 mg/dL (10 g/L) (as detected with serum protein electrophoresis [SPEP] and confirmed by immunofixation [IFIX] ) and a serum viscosity greater than our laboratory's reference value of 1.55 cP (as measured by rotational viscometry). Thirty-seven patients with an IgM gammopathy and a concomitant serum hyperviscosity were seen at our hospital from January 1994 through August 1999, a period of more than 5 years. The anatomic pathology records of these patients then were searched for tissue diagnoses of lymphoma or suspected lymphoma. After excluding cases for which only bone marrow biopsy specimens were available, adequate histologic material(s) for 12 patients was on file at our hospital. All available pathologic material from each of these cases was retrieved and reviewed with the diagnoses classified according to the Revised European-American classification of lymphoid neoplasms (REAL) and proposed World Health Organization (WHO) classification guidelines. 6, 11 Four additional cases of EMZL/MALT-type associated with WM were identified in this manner, for a total of 6 cases studied.
Morphologic Features and Classification
Cases were diagnosed as EMZL/MALT-type if they met the following criteria. (1) They primarily involved and/or were first diagnosed in extranodal tissues such as stomach, salivary gland, ocular adnexa, lung, and skin (ie, recognized MALT sites). (2) They were cytologically composed of heterogeneous mixtures of small B lymphocytes, marginal zone B cells, monocytoid B cells, and plasma cells. (3) They demonstrated diffuse, perifollicular, and/or interfollicular patterns of involvement along with occasional reactive follicles, areas of follicular colonization, and lymphoepithelial lesions.
Consistent with the REAL classification guidelines, patients with biopsy specimens showing small lymphocytes, plasmacytoid lymphocytes, and plasma cells (with or without Dutcher bodies) but lacking the above-described morphologic features of EMZL/MALT-type were diagnosed as LPL and excluded from the study. Cases with histopathologic features of the provisional REAL entity, splenic marginal zone lymphoma, which is reported to have an associated Mcomponent in approximately 40% of cases, 6 and patients with clinicopathologic findings suggestive of multiple myeloma also were excluded. The histologic findings of all 6 cases subsequently were correlated with all other available laboratory and clinical data.
Immunophenotyping
Immunophenotyping by avidin-biotin complex immunoperoxidase staining and/or 2-or 3-color flow cytometric analysis using previously described methods 12 was used to verify the B-cell phenotype of these lymphomas, to confirm immunoglobulin light chain restriction, and to exclude other lymphomas such as follicle center cell lymphoma, mantle cell lymphoma, and CLL/SLL. Briefly, for immunohistochemical analysis, formalin-and/or B5-fixed, paraffin-embedded tissues from all cases were deparaffinized in xylene and alcohol and subsequently stained for a panel of antibodies including those listed in ❚Table 1❚. Antigen retrieval was performed by microwaving tissue sections in a 10-mmol/L concentration of citrate buffer (pH 6.0) for CD20, CD45RO, and CD43 or a 0.25-mol concentration of tris(hydroxymethyl)aminomethane/0.1-mmol/L concentration of EDTA (pH 9) for CD5 and CD10 inside a pressure cooker (Tender Cooker, Nordic Ware, Minneapolis, MN). The immunohistochemical staining was carried out using an automated stainer at 37°C to 42°C (Ventana ES, Ventana Medical Systems, Tucson, AZ) with an avidin-biotin-peroxidase complex. For flow cytometric analysis, mononuclear cell suspensions from 4 of 6 cases were obtained by mechanical disaggregation and subsequent Ficoll-Hypaque density gradient centrifugation. Surface membrane immunophenotyping was performed with an EPICS XL-MCL (Beckman-Coulter, Miami, FL) flow cytometer using the panel of antibodies listed in Table 1 . Samples for flow cytometric analysis were not submitted for 2 cases.
Results
After complete clinicopathologic review and classification, 4 men and 2 women (age range, 40-79 years; mean, 60.6 years) met published criteria for the diagnosis of EMZL/MALT-type. Recognized anatomic MALT lymphoma sites, including lung (2), pericardium and pleura (1), ocular adnexa (2), nasopharynx (1), labial minor salivary gland (1), glossopharyngeal fold (1), skin (1), and stomach (1), were involved by lymphoma in all 6 cases. While all patients had involvement of at least 1 MALT site at diagnosis, multiple extranodal sites of disease (excluding the bone marrow) were documented during the course of disease in 3 of 6 cases. Nodal involvement was present in 4 patients (2 at diagnosis), and the disease was disseminated to the bone marrow in 3 patients (2 at diagnosis). Chronic inflammatory processes with recognized relationships to MALT lymphoma 8 were present in 2 cases. Specifically, a patient with gastric MALT lymphoma had been diagnosed previously with and treated for Helicobacter pylori gastritis, and another patient with EMZL/MALT-type involving a minor salivary gland had been diagnosed with Sjögren syndrome and rheumatoid arthritis several years before lymphoma was diagnosed. Demographic and clinicopathologic data are summarized in ❚Table 2❚.
In all 6 patients, biopsy specimens from anatomic MALT sites showed the characteristic cellular and architectural features of EMZL/MALT-type as described in several previously published reports as well as in the REAL and proposed WHO lymphoma classifications. 6, 11, [13] [14] [15] [16] [17] The involved extranodal sites contained heterogeneous populations of neoplastic cells consisting of small B lymphocytes, small to medium-sized B cells with abundant cytoplasm (marginal zone or centrocyte-like), larger B cells with more nuclear irregularity and more abundant pale cytoplasm (monocytoid B cells), and plasma cells; occasional large, transformed cells (centroblast-or immunoblast-like) also were present in most cases. Reactive follicles, often with neoplastic cells within the marginal zone and/or in the interfollicular region, were seen in some cases.
Characteristic lymphoepithelial lesions resulting from the infiltration of marginal zone B cells into the epithelium were present and highlighted by cytokeratin immunostaining in 4 cases. In all cases, plasma cells often were found in distinct subepithelial or interfollicular zones; light chain restriction was demonstrated by immunohistochemical analysis for kappa and lambda light chains using formalinfixed, paraffin-embedded tissue sections in 2 cases and by both immunohistochemical and flow cytometric analyses in the other 4 cases. Alternative diagnoses including follicle center cell lymphoma, mantle cell lymphoma, and CLL/SLL were excluded using immunohistochemical analysis and flow cytometric immunophenotyping. The neoplastic lymphocytes in all 6 cases were positive for CD20 and negative for CD5, CD10, and cyclin D1 by immunohistochemical analysis. Coexpression of CD43 on the B lymphocytes was found in 3 of 6 cases. B-cell clonality was further documented by flow cytometric analysis in all 4 cases analyzed by this technique. Representative images from these 6 cases of EMZL/MALT-type are shown in ❚Image 1❚, ❚Image 2❚, and ❚Image 3❚.
SPEP and IFIX studies revealed a monoclonal IgM kappa paraproteinemia in 4 of 6 cases (range, 3,200-8,800 While recommended by the laboratory in 5 of the 6 cases, plasma viscosity was measured in only 4 of 6; however, it was elevated in all 4 (range, 2.6-7.4 cP; mean, 4.9 cP; reference range, <1.55 cP). Clinical manifestations of HVS, including bleeding diathesis (2), visual changes (1), mental status changes (2), and generalized weakness (2) were present in 3 of the 4 patients with measured plasma hyperviscosity. Furthermore, 1 patient had severe cardiactype chest pain in addition to epistaxis and visual disturbances. Emergency therapeutic plasmapheresis was required by 2 of the symptomatic patients, while the other responded to conservative management, which included hydration. Multiple total plasma exchange procedures were necessary before the symptoms of HVS resolved in the 2 patients needing plasmapheresis. Repeated courses of total plasma exchange also were performed for 1 asymptomatic patient with a plasma viscosity of 2.71 cP and a 6,600 mg/dL (66 g/L) IgM paraproteinemia. In addition to the monoclonal restriction, suppression of the background immunoglobulins (hypogammaglobulinemia) was observed on the SPEP gels in 4 of the 6 cases. Subsequent urine protein electrophoresis and urine IFIX studies were performed in 3 of 6 cases, and Bence Jones proteinuria was found in 2 of the 3 patients. Free kappa light chains alone were present in both patients, while free kappa light chains and intact IgM kappa were found in 1 patient. Importantly, the latter patient had evidence of renal insufficiency at the time of these findings. Serum creatinine levels were within normal limits in all other patients. Although 1 patient experienced a sensorimotor peripheral neuropathy that was thought to be the result of the IgM gammopathy, other less common manifestations of macroglobulinemia were not observed in this group of patients. Results of diagnostic serum and urine studies for all 6 patients are summarized in Table 2 , and representative results are illustrated in ❚Figure 1❚. Similarly, the reported macroglobulinemic complications are shown in Table 2 .
The monoclonal gammopathy and lymphoma were found concurrently in 2 patients, and 1 patient had HVS secondary to a 3,200 mg/dL (32 g/L) IgM paraproteinemia 1 month before the diagnosis of MALT lymphoma was made. The diagnosis of EMZL/MALT-type preceded the observation of serum macroglobulinemia in the remaining 3 patients by an average of 47 months (range, 16-84 months). Treatment with multiple cycles of systemic chemotherapy was given to 5 of 6 patients (cyclophosphamide, vincristine, and prednisone [CVP], 3 patients; chlorambucil and prednisone, 1 patient; cyclophosphamide, doxorubicin, and vincristine, 1 patient; fludarabine, 4 patients). Four of these 5 were treated for progressed disease and/or macroglobulin-related complications after diagnosis with monoclonal gammopathy; 1 patient was treated with CVP for high-stage disease at diagnosis (before macroglobulinemia was observed). Among the group treated with systemic chemotherapy was 1 patient who was given CVP following relapse with disseminated disease 6 years after having received local radiation therapy for MALT lymphoma limited to the lung. In general, relapses tended to occur in the same site involved at diagnosis and/or in other epithelial sites as is typical of disseminated EMZL /MALT-type. At last available follow-up, 4 of the 5 patients requiring systemic chemotherapy were still being treated with fludarabine. Local radiation therapy alone was administered to 1 patient with EMZL /MALT-type involving the ocular adnexa; this patient's disease recurred in the glossopharyngeal fold 3 months later, but he was shortly thereafter lost to follow-up, and additional data on therapy or outcome were unavailable. A summary of the administered therapeutic regimens is shown in ❚Table 3❚.
Discussion
Waldenström macroglobulinemia is a clinicopathologic syndrome in which the major clinical manifestations and complications are directly attributed to high levels of monoclonal paraprotein produced by the associated lymphoma. [2] [3] [4] This monoclonal immunoglobulin, which is usually but not always of the IgM class, can cause cryoglobulinemia, cold agglutinin disease, and hyperviscosity when present in the circulation, and amyloidosis, glomerular disease, or neuropathy when it accumulates in tissues. 3 HVS, which is seen in approximately 15% of patients with WM, is the most serious and potentially fatal complication of macroglobulinemia. 3 While the association between high levels of circulating macroglobulin and infiltration of the bone marrow by plasmacytoid lymphocytes was recognized by Waldenström in his original description of this entity, 5 WM is now more specifically defined as an IgM monoclonal gammopathy associated with LPL or other neoplastic small lymphocyte proliferations such as SLL. 1, 6, 11 As defined by many authors and advanced in the REAL and proposed WHO classifications of lymphoid neoplasms, LPL (immunocytoma) is morphologically characterized by an infiltrate of small lymphocytes, plasmacytoid lymphocytes, and plasma cells (with or without Dutcher or Russell bodies) involving the bone marrow, lymph nodes, spleen, and blood and lacking the immunomorphologic features of B-cell CLL/SLL, follicle center cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma. 1, 6, 11, 17 With more than 75% of LPL cases being associated with a monoclonal macroglobulinemia, the causal relationship of LPL to WM is well established. On the other hand, the association of clinically significant macroglobulinemia with other types of non-Hodgkin lymphoma (excluding CLL/SLL) has been the subject of only rare case reports. 7, 9, 10, 18 In 1996, Abe et al 9 reported a case of a 48-year-old man with low-grade non-Hodgkin lymphoma involving the palatine tonsils and bone marrow, but not the lymph nodes, associated with a 3,900 mg/dL (39 g/L) IgM kappa spike, elevated serum viscosity, and Bence Jones proteinuria. While the provided histologic description and published images in their report resemble EMZL/MALTtype, a translocation between the long arms of chromosomes 14 and 18 was found by routine cytogenetics, and the case was classified as a follicular lymphoma. Complications of macroglobulinemia, such as HVS, were not reported.
Three cases of EMZL/MALT-type occurring in patients with either IgM or IgA paraproteinemias greater than 1,000 mg/dL (10 g/L) have been reported in 2 separate publications. 7, 10 The case of a 61-year-old man with low-grade Bcell lymphoma of MALT-type involving the thymus associated with a 1,700 mg/dL (17 g/L) IgA lambda restriction, a mixed IgA-IgG cryoglobulin, and Sjögren syndrome was described by Yamasaki et al 10 in 1998. The additional 2 cases, reported by Allez et al, 7 included a 31-year-old man with low-grade gastrointestinal MALT lymphoma involving the bone marrow and occurring with a 2,900 mg/dL (29 g/L) IgM kappa restriction, and a 71-year-old man also with disseminated low-grade gastrointestinal MALT lymphoma and a 3,100 mg/dL (31 g/L) IgM lambda monoclonal gammopathy. While all 3 of the aforementioned cases of EMZL/MALT-type had paraproteinemias greater than 1,000 mg/dL (10 g/L), complications of macroglobulinemia were not reported.
We now describe the clinicopathologic characteristics of 6 patients with well-documented low-grade EMZL/ MALT-type associated with the syndrome of WM to emphasize the association of these entities and to stress the role of serum studies, and possibly even urine protein studies, in the evaluation of patients with EMZL/MALT-type. All 6 patients described in this article had low-grade B-cell lymphomas that manifested in and/or primarily involved socalled MALT lymphoma sites, and each met the diagnostic criteria for EMZL/MALT-type as described in several previously published reports. In addition, all 6 patients with EMZL/MALT-type were found to have macroglobulinemias greater than 1,000 mg/dL (10 g/L) during the course of their disease, with 4 patients also demonstrating definite clinical complications of WM. Moreover and importantly, 3 patients required hospitalization and emergency treatment (including several courses of TPE in 2 cases) for HVS, and 5 are known to have needed systemic chemotherapy for disease control.
While the morphologic distinction between LPL and EMZL/MALT-type sometimes can be difficult because of the occasional similar cytologic composition of these lymphomas (particularly with respect to the presence of plasmacytoid lymphocytes and plasma cells), several histopathologic and clinical features allowed us to confidently classify these 6 cases as EMZL/MALT-type. First, all patients had disease involving at least one epithelial site at diagnosis, and in several cases, multiple MALT sites were involved as the disease progressed. This pattern of dissemination from one mucosal or epithelial site to another is characteristic of MALT lymphomas and unusual for LPL, which predominantly involves the bone marrow, blood, lymph nodes, and spleen and rarely occurs primarily in extranodal sites. 8, 14 Moreover, the lungs, skin, and gastrointestinal tract are unusual sites of involvement by LPL. 3 The mere involvement of extranodal epithelial sites is an important feature in the distinction between EMZL/MALT-type and LPL, as many experts propose that extranodal lymphoplasmacytoid proliferations should be considered consistent with MALT-type lymphoma rather than immunocytoma. 8 Second, the morphologic findings observed in these cases, including the presence of marginal zone and monocytoid B cells, small lymphocytes, variable numbers of plasma cells, and occasional centroblasts and immunoblasts along with reactive germinal centers, follicular colonization, and lymphoepithelial lesions, are characteristic of EMZL/MALT-type and not typical of LPL. While these cytologic and architectural features alone argue against LPL, some authors also would exclude the diagnosis of immunocytoma based solely on the fact that histologic features of another type of lymphoma were present in these cases. 6 Last, the presence of preceding chronic inflammatory diseases with known associations to MALT lymphomas (but not with LPL) in 2 patients adds further support to the diagnosis of EMZL/MALT-type in these cases. Although bone marrow and/or nodal involvement was documented in some of the patients in the present study, these findings are most likely the result of disease progression or dissemination, and they should not weigh against the classification of these cases as MALT lymphomas, since it has been shown that these usually indolent neoplasms disseminate in up to 30% of cases 6 and involve the bone marrow in up to 46%. 19 The combination of histologic, clinical, and laboratory features observed in the 6 patients described in this article not only demonstrate a definite relationship between EMZL/MALT-type and the clinicopathologic syndrome of WM but also strongly suggest that WM can be caused by EMZL/MALT-type. Consequently, serum studies including SPEP and IFIX may have an important role in the evaluation and management of patients with EMZL/MALT-type. Plasma viscosity measurements, urine protein electrophoresis and
